Skip to main content
Retour
REGN logo

Regeneron Pharmaceuticals, Inc.

Qualité des données : 100%
REGN
NASDAQ Healthcare Biotechnology
736,53 €
▲ 3,66 € (0,50%)
Cap. Boursière : 76,53B
Fourchette du Jour
735,40 € 750,00 €
Fourchette 52 Semaines
476,49 € 821,11 €
Volume
510 002
Moyenne 50J / 200J
766,57 € / 651,78 €
Clôture Précédente
732,87 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (626 pairs)

Métrique Action Médiane du Secteur
P/E 17,0 0,4
P/B 2,5 2,9
ROE % 14,9 3,7
Net Margin % 31,4 3,9
Rev Growth 5Y % -2,8 10,0
D/E 0,1 0,2

Objectif de Cours des Analystes

Hold
862,74 € +17.1%
Low: 700,00 € High: 1 057,00 €
P/E Prévisionnel
16,2
BPA Prévisionnel
45,38 €
Croissance BPA (est.)
+0,0%
CA Est.
16 B

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2030 71,97 €
64,90 € – 79,90 €
21 B 2
FY2029 67,38 €
60,76 € – 74,80 €
20 B 4
FY2028 60,83 €
48,91 € – 72,26 €
19 B 6

Points Clés

Revenue declined -2,81% annually over 5 years
ROE of 14,87% — decent returns on equity
Net margin of 31,41% shows strong profitability
Debt/Equity of 0,09 — conservative balance sheet
Generating 4,08B in free cash flow
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 3,80%

Croissance

Revenue Growth (5Y)
-2,81%
Revenue (1Y)0,99%
Earnings (1Y)2,09%
FCF Growth (3Y)5,48%

Qualité

Return on Equity
14,87%
ROIC7,90%
Net Margin31,41%
Op. Margin24,95%

Sécurité

Debt / Equity
0,09
Current Ratio4,13
Interest Coverage81,69

Valorisation

P/E Ratio
16,99
P/B Ratio2,45
EV/EBITDA21,27
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 0,99% Revenue Growth (3Y) 4,57%
Earnings Growth (1Y) 2,09% Earnings Growth (3Y) 6,74%
Revenue Growth (5Y) -2,81% Earnings Growth (5Y) -13,58%
Profitability
Revenue (TTM) 14,34B Net Income (TTM) 4,50B
ROE 14,87% ROA 11,11%
Gross Margin 85,35% Operating Margin 24,95%
Net Margin 31,41% Free Cash Flow (TTM) 4,08B
ROIC 7,90% FCF Growth (3Y) 5,48%
Safety
Debt / Equity 0,09 Current Ratio 4,13
Interest Coverage 81,69 Dividend Yield 0,00%
Valuation
P/E Ratio 16,99 P/B Ratio 2,45
P/S Ratio 5,34 PEG Ratio 3,38
EV/EBITDA 21,27 Dividend Yield 0,00%
Market Cap 76,53B Enterprise Value 76,12B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 14,34B 14,20B 13,12B 12,17B 16,07B
Net Income 4,50B 4,41B 3,95B 4,34B 8,08B
EPS (Diluted) 41,48 38,34 34,77 38,22 71,97
Gross Profit 12,24B 12,23B 10,87B 10,47B 13,35B
Operating Income 3,58B 3,99B 4,35B 5,39B 8,95B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 40,56B 37,76B 33,08B 29,21B 25,43B
Total Liabilities 9,30B 8,41B 7,11B 6,55B 6,67B
Shareholders' Equity 31,26B 29,35B 25,97B 22,66B 18,77B
Total Debt 2,71B 2,70B 2,70B 2,70B 2,70B
Cash & Equivalents 3,12B 2,49B 2,73B 3,11B 2,89B
Current Assets 18,02B 18,66B 19,48B 15,88B 14,01B
Current Liabilities 4,37B 3,94B 3,42B 3,14B 3,93B